Efficacy of topical tacrolimus 0.1 in active plaque morphea: Randomized, double-blind, emollient-controlled pilot study

American Journal of Clinical Dermatology

Volumn 10, Issue 3, 2009, Pages 181-187

  Kroft, Elisabeth B M ^a   Groeneveld, Tamara J ^a   Seyger, Marieke M B ^a   De Jong, Elke M G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EMOLLIENT AGENT; PETROLATUM; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; MALE; MORPHEA; OINTMENT; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCLERODERMA;

ADULT; AGED; DOUBLE-BLIND METHOD; EMOLLIENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; OINTMENTS; PETROLATUM; PILOT PROJECTS; SCLERODERMA, LOCALIZED; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 64849098185     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200910030-00004     Document Type: Article

References (37)

1. Assmann T, Homey B, Ruzicka T. Applicationsof tacrolimus for the treatment of skin disorders. Immunopharmacology 2000; 47: 203-13
2. Zulian F. Systemic manifestations in localized scleroderma. Curr Rheumatol Rep 2004; 6: 417-24
3. Alecu M, Geleriu L, Coman G, et al. The interleukin-1, interleukin-2, inter-leukin-6 and tumour necrosis factor alpha serological levels in localised and systemic sclerosis. Rom J Intern Med 1998; 36: 251-9
4. Hasegawa M, Sato S, Nagaoka T, et al. Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. Dermatology 2003; 207: 141-7
5. Ihn H, Sato S, Fujimoto M, et al. Demonstration of interleukin 8 in serum samples of patients with localized scleroderma. Arch Dermatol 1994; 130:1327-8
6. Ihn H,Sato S, Fujimoto M, etal. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res 1995; 287: 193-7
7. Chung L, Lin J, Furst DE, et al. Systemic and localized scleroderma. Clin Dermatol 2006; 24: 374-92
8. Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin Proc 1995; 70: 1068-76
9. Joly P, Bamberger N, Crickx B, et al. Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients. Arch Dermatol 1994; 130: 663-4
10. Dytoc M, Ting PT, Man J, et al. First case series on the use of imiquimod for morphoea. Br J Dermatol 2005; 153: 815-20
11. Aragane Y, Kawada A, Maeda A, et al. Disseminated scleroderma of a Japanese patient successfully treated with bath PUVA photochemotherapy. J Cutan Med Surg 2001; 5: 135-9
12. Kreuter A, Gambichler T, Breuckmann F, et al. Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized sclero-derma. Arch Dermatol 2005; 141: 847-52
13. Seyger MM, van Den Hoogen FH, de Boo T, et al. Low-dose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol 1998; 39: 220-5
14. Uziel Y, Feldman BM, Krafchik BR, et al. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr 2000; 136: 91-5
15. Falanga V, Medsger Jr TA. D-penicillamine in the treatment of localized scleroderma. Arch Dermatol 1990; 126: 609-12
16. Hunzelmann N, Anders S, Fierlbeck G, et al. Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma. J Am Acad Dermatol 1997; 36: 433-5
17. Kreuter A, Hyun J, Stucker M, et al. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol 2006; 54: 440-7
18. Mancuso G, Berdondini RM. Topical tacrolimus in the treatment of localized scleroderma. Eur J Dermatol 2003; 13: 590-2
19. Mancuso G, Berdondini RM. Localized scleroderma: response to occlusive treatment with tacrolimus ointment. Br J Dermatol 2005; 152: 180-2
20. Walker JG, Pope J, Baron M, et al. The development of systemic sclerosis classification criteria. Clin Rheumatol 2007; 26: 1401-9
21. Tuffanelli DL. Localized scleroderma. Semin Cutan Med Surg 1998; 17: 27-33
22. Zachariae H, Bjerring P, Halkier-Sorensen L, et al. Skin scoring in systemic sclerosis: a modification. Relations to subtypes and the aminoterminal pro-peptide of type III procollagen (PIIINP). Acta Derm Venereol 1994; 74: 444-6
23. Kissin EY, Schiller AM, Gelbard RB, et al. Durometry for the assessment of skin disease in systemic sclerosis. Arthritis Rheum 2006; 55: 603-9
24. Seyger MM, van den Hoogen FH,de Boo T,et al. Reliability oftwo methods to assess morphea: skin scoring and the use of a durometer. J Am Acad Dermatol 1997; 37: 793-6
25. Zulian F, Meneghesso D, Grisan E, et al. A new computerized method for the assessment of skin lesions in localized scleroderma. Rheumatology (Oxford) 2007; 46: 856-60
26. Goto T, Kino T, Hatanaka H, et al. Discovery of FK-506, a novel immuno-suppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987; 19: 4-8
27. Brune A, Miller DW, Lin P, et al. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol 2007; 24: 76-80
28. Simpson D, Noble S. Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs 2005; 65: 827-58
29. Rustin MH. The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review. Br J Dermatol 2007; 157: 861-73
30. Bohm M, Frieling U, Luger TA, et al. Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch Dermatol 2003; 139: 922-4
31. Matsumoto Y, Yamamoto T, Isobe T, et al. Successful treatment of vulvar lichen sclerosus in a child with low-concentration topical tacrolimus ointment. J Dermatol 2007; 34: 114-6
32. Virgili A, Lauriola MM, Mantovani L, et al. Vulvar lichen sclerosus: 11 women treated with tacrolimus 0.1% ointment. Acta Derm Venereol 2007; 87: 69-72
33. Hawk A, English III JC. Localized and systemic scleroderma. Semin Cutan Med Surg 2001; 20: 27-37
34. Robinson N, Singri P, Gordon KB. Safety of the new macrolide immunomodulators. Semin Cutan Med Surg 2001; 20: 242-9
35. Kikuchi K, Tagami H. Comparison of the effects of daily applications between topical corticosteroid and tacrolimus ointments on normal skin: evaluation with noninvasive methods. Dermatology 2002; 205: 378-82
36. Kyllönen H, Remitz A, Mandelin JM, et al. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol 2004; 150: 1174-81
37. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998; 111: 396-8